Pancreatic cancer has a grim prognosis. It is usually detected after the disease has spread, and chemotherapy tends to do little to slow the cancer’s growth. Even with treatment, most patients live only about six months after they are diagnosed with the disease.
Researchers in Professor David Tuveson’s laboratory at Cold Spring Harbor Laboratory (CSHL) think it’s possible to do better with a different type of treatment. Part of the problem, they say, is that cancer cells in the pancreas are protected by the dense matrix that surrounds them. The matrix is a mixture of extracellular components and noncancerous cells known as the stroma. All solid tumors contain stroma. In pancreatic cancers, this fibrous material is particularly abundant, making up nearly 90 percent of a tumor’s mass. This stroma impedes anticancer drugs’ from getting to their targets. Additionally, stromal cells secrete factors that actually help the tumors grow.
Overcoming the stroma’s protective influence has been challenging, but new leads from Tuveson’s team, as reported on October 26, 2018 in the journal Cancer Discovery, point to a promising strategy. In fact, the new findings suggest that drugs which target the right cellular pathways can do more than just thwart tumor-supporting cells in the stroma. They may recruit them into the anticancer fight.
A key element of the stroma is a type of cell called a fibroblast. Fibroblasts manufacture the stroma’s connective tissue. They also generate factors that promote cancer cell growth and prevent the immune system from attacking the cancerous cells. Last year Tuveson’s team discovered that the stroma of pancreatic tumors contains at least two types of fibroblasts. One type show features known to support tumor growth, the other type appear to have the opposite effect.
The good news is that the fibroblasts’ identities are not fixed. With the right cues, tumor-promoting fibroblasts can become tumor-restrictors.
“These cells can convert into one another, depending on the cues they get from the microenvironment and from the cancer cells,” explains Giulia Biffi, a postdoctoral researcher in Tuveson’s lab who led the new study. “This is potentially useful because, in theory, you can shift the tumor-promoting cells to tumor-restraining, rather than just depleting the tumor-promoting cells.”
In this new report, Biffi and her colleagues have identified specific molecular signals released by cancer cells that determine fibroblasts’ character within pancreatic tumors. They have discovered that one such molecule, IL-1, drives fibroblasts to take on a tumor-promoting identity. They have also shown how another molecule, TGF-beta, overrides that signal and keeps fibroblasts in a potentially anticancer state even when IL-1 is present.
The researchers are now exploring what happens to pancreatic tumors when they manipulate IL-1 and TGF-beta signaling and convert tumor-promoting fibroblasts to a more beneficial state. They will also investigate what happens when they target these pathways in combination with chemotherapy or cancer immunotherapies. Ultimately, Biffi says, patients may benefit most from a combination of therapies that target both the cancer cells and parts of the microenvironment that support their growth.
Learn more: Turning cells against pancreatic cancer
Receive an email update when we add a new PANCREATIC CANCER article.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Good Day NWA: National Pancreatic Cancer Awareness Month on November 13, 2018 at 10:00 am
November marks National Pancreatic Cancer Awareness Month and the Pancreatic Cancer Action Network is urging you to demand better for patients affected by the world's toughest cancer. Jennifer Allison ... […]
- November is Pancreatic Cancer Awareness Month – do you know the symptoms? on November 13, 2018 at 9:23 am
November is Pancreatic Cancer Awareness Month. Pancreatic cancer is one of the nation’s deadliest cancers with a five-year survival rate of just 9 percent. It’s a disease that kills more people than b... […]
- Medpace conducting ‘Cell-in-a-Box’ trial targeting pancreatic cancer on November 13, 2018 at 8:35 am
PharmaCyte Biotech has contracted Medpace to conduct the clinical trial using its novel live-cell encapsulation technology, Cell-in-a-Box, which the company says could revolutionize cancer treatment. ... […]
- Pancreatic cancer's addiction could be its end on November 13, 2018 at 8:07 am
The researchers looked for various indicators of tumor activity in normal pancreas cells (top row) comparing results to those from when the production of the P63 protein has been inappropriately ... […]
- KNWA Today: November is National Pancreatic Cancer Awareness Month on November 13, 2018 at 4:40 am
NORTHWEST ARKANSAS (KNWA) - November marks National Pancreatic Cancer Awareness Month and the Pancreatic Cancer Action Network is urging you to demand better for patients affected by the world's tough... […]
- In Touch w/ Jeff Smith - Pancreatic Cancer on November 12, 2018 at 9:29 am
- However, it is considered an uncommon cancer in comparison to other cancers like breast and colon cancer. - Unfortunately, pancreatic cancer is often found at a late stage and has a poorer prognosis ... […]
- RIP1 Kinase identified as promising therapeutic target in pancreatic cancer on November 12, 2018 at 8:09 am
Axial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domain An experimental drug may be effective against a deadly form of pancreatic cancer when ... […]
- Health Matters: An Option for Pancreatic Cancer on November 12, 2018 at 6:48 am
It’s a common diagnosis. Studies show Florida has the third highest incidence of pancreatic cancer in the country. “Survivals are better marginally than they have been in the past but we have a long, ... […]
- Pancreatic cancer: What everyone should know on November 12, 2018 at 6:36 am
Nov. 11, 2018—If this year is typical, about 42,000 people in the U.S. will learn they have pancreatic cancer. It's the fourth leading cancer killer nationwide. And a key reason is that it's hard to d... […]
via Bing News